Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Insmed Announces Positive Topline Results From Phase 3 ARISE Study of ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with NTM Lung Disease Caused by MAC
Transient Aerosol Measurements: Assessing the eFlow Nebulizer Aerosol Bolus.
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Large-eddy simulation, convective instability, and modal causality of coaxial supersonic air–water jets considering a swirl effect.
Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)
